Lastly, our preclinical xenograft studies identified epidermal growth factor receptor (EGFR) T cell immunotherapy as a promising new therapy in a large fraction of pediatric RMSs. This evidence concerns the gene EGFR and Bannayan-Riley-Ruvalcaba syndrome.